The effects of an HIV‐1 immunogen (Remune) on viral load, CD4 cell counts and HIV‐specific immunity in a double‐blind, randomized, adjuvant‐controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs

Abstract

These results suggest that, in a predefined, random subset of subjects, a beneficial effect of the HIV-1 immunogen was observed on viral load, CD4+ T cells, and HIV-specific immunity. These differences were observed in a background of multiple drug therapies. Ongoing trials are evaluating the effect of the combination of this HIV-1 specific, immune-based therapy with potent antiviral drug therapy on virological outcomes.